Disease · HP_0001269
Hemiparesis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Hemiparesis. Diseases, record HP_0001269. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001269
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hemiparesis
- Open Targets ID
- HP_0001269
- Other names
- Weakness of one side of body
- Highest stage of its drugs
- Phase 3, for 2 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| CYCLOSERINE | CHEMBL771 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOXETINE | CHEMBL41 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | 2 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6334 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02208466 | Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients | Phase 2 | 44 | 2021-02-21 | Stroke, Motor Function | FLUOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT01422161 | Study of Botulinum Toxin and Recovery of Hand Function After Stroke | Phase 3 | 16 | 2019-05-31 | Stroke With Hemiparesis | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT02082912 | NMDA Receptors in Motor Learning in Humans | Phase 2 | 14 | 2015-04-22 | Stroke | CYCLOSERINE | Its record names the disease | ClinicalTrials.gov |
| NCT03119948 | Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis | Phase 2 | 66 | Hemiparesis After Stroke, Traumatic Brain Injury | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov | |
| NCT01821573 | Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients | Phase 3 | 36 | COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov | |
| NCT00907829 | Source of Hand Weakness After Stroke | Phase 2 | 0 | Stroke, Cerebrovascular Accident | LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Botulinum Toxin Commonly Known as BOTOX® vs Placebo: deaths from any cause | 0 of 10 | 0 of 6 | 16 | NCT01422161 | Trial comparisons |
| Botulinum Toxin Commonly Known as BOTOX® vs Placebo: serious adverse events | 0 of 10 | 0 of 6 | 16 | NCT01422161 | Trial comparisons |
| D-cycloserine vs Placebo: deaths from any cause | 0 of 7 | 0 of 7 | 14 | NCT02082912 | Trial comparisons |
| D-cycloserine vs Placebo: serious adverse events | 0 of 7 | 0 of 7 | 14 | NCT02082912 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001269
GET https://conductscience.org/api/diseases/v1/HP_0001269/drugs